Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,226.50GBp
10:01am EDT
Change (% chg)

62.00 (+1.49%)
Prev Close
4,164.50
Open
4,183.00
Day's High
4,240.00
Day's Low
4,137.42
Volume
2,109,496
Avg. Vol
2,747,766
52-wk High
5,377.00
52-wk Low
4,025.00

Select another date:

Tue, Jul 18 2017

BRIEF-Novimmune and Shire sign license agreement deepening bispecific antibody research collaboration​

* ‍NOVIMMUNE AND SHIRE SIGN LICENSE AGREEMENT DEEPENING BISPECIFIC ANTIBODY RESEARCH COLLABORATION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Shire, Roche slug it out in billion-dollar haemophilia drug battle

ZURICH Swiss drugmaker Roche's bid to take a chunk of the $11 billion haemophilia drug market dominated by Shire took another blow with the Irish company winning a preliminary injunction over its Swiss rival's medication.

UPDATE 2-Shire, Roche slug it out in billion-dollar haemophilia drug battle

* Share of big $11 bln haemophilia market at stake (Adds details from preliminary injunction in paragraphs 8, 9)

Roche, Shire court fight underscores high stakes in haemophilia

ZURICH, July 10 Roche's bid to muscle in on Shire's share of the $11 billion haemophilia drug market took a new, contentious turn this weekend when the British drugmaker won a court injunction against how the Swiss drugmaker talks about its new medicine.

Shire gets injunction against Roche over hemophilia drug

ZURICH Pharmaceutical group Shire said on Sunday it had obtained a preliminary injunction in a Hamburg court against rival Roche over its hemophilia drug emicizumab, alleging incomplete and misleading statements surrounding the treatment.

Shire gets injunction against Roche over haemophilia drug

ZURICH, July 9 Pharmaceutical group Shire said on Sunday it had obtained a preliminary injunction in a Hamburg court against rival Roche over its haemophilia drug emicizumab, alleging incomplete and misleading statements surrounding the treatment.

BRIEF-Shire submits IND application for gene therapy candidate SHP654

* Shire submits investigational new drug application to FDA for gene therapy candidate SHP654 for treatment of Hemophilia A

BRIEF-Supernus says Shire receives FDA approval for Mydayis for ADHD

* Supernus announces that its partner Shire receives FDA approval for Mydayis™ for ADHD

Shire wins U.S. approval for long-acting ADHD drug

Shire has won U.S. approval for a long-acting attention deficit drug aimed at adolescents and adults, boosting its stock of medicines for the cognitive condition that affects millions of children and is being diagnosed more in older people.

UPDATE 1-Shire wins U.S. approval for long-acting ADHD drug

* Shares up 1.5 percent in London trading (Adds sales forecasts, shares, reaction)

Select another date: